uniQure N.V.
http://www.uniqure.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From uniQure N.V.
Pfizer’s Hympavzi May Fall Into Hemophilia B Niche
The US FDA approved the drug for hemophilia A and B, and while it may struggle to compete in hemophilia A against Roche’s Hemlibra, it has a big convenience advantage in hemophilia B.
Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited
The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.
Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited
The withdrawal amid concerns about the risk-benefit ratio reduces treatment options for sickle cell disease, but it is not expected to have much effect on the SCD market, including the gene therapies.
Stock Watch: Bad Deals Backfire On Bayer And CSL
As the pharma earnings season wrapped up, it seemed like a contest to see which company's stock price dropped the most after their announcement and which made the poorest acquisition.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Amsterdam Molecular Therapeutics (AMT)
- Corlieve Therapeutics SAS
- InoCard GmbH
- uniQure Germany GmbH
- uniQure U.S.A.
- uniQure The Netherlands
- uniQure Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice